Berkshire Hathaway on Track for Record High Close — Data Talk
Berkshire Hathaway Inc. Class B (BRKB) is currently at $482.80, up $5.97 or 1.25%
--Would be new all-time high (Based on available data back to May 9, 1996)
--Currently up nine consecutive days; up 8.11% over this period
--Longest winning streak since April 18, 2023, when it rose for nine straight trading days
--Best nine day stretch since the nine days ending July 17, 2024, when it rose 9.82%
--Up 35.37% year-to-date
--Up 33.49% from 52 weeks ago (Sept. 6, 2023), when it closed at $361.67
--Would be a new 52-week closing high
--Up 45.55% from its 52-week closing low of $331.71 on Oct. 27, 2023
--Traded as high as $484.82; new all-time intraday high (Based on available data back to May 9, 1996)
--Up 1.68% at today's intraday high
All data as of 10:09:24 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 04, 2024 10:26 ET (14:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks